Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

PM359

Cell therapy (Gene-edited cells) · Gene replacement · developed by Prime Medicine

Phase 1/2 Most advanced trial

PRME Developer

1 Registered trials

What is PM359?

PM359 is an autologous cell therapy for chronic granulomatous disease. Patient cells are gene-edited ex vivo and reinfused following myeloablative conditioning.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (Gene-edited cells)
Mechanism: Gene replacement
Therapy area: Immunology
Developer: Prime Medicine, Inc. (PRME)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06559176	Phase 1/2	Chronic Granulomatous Disease	Enrolling by invitation	PRME

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Granulomatous DiseaseGranulomatous Disease, Chronic

More from Prime Medicine

PG-011 Phase 3 PG-011Gel Phase 3 PG-033 Phase 1 PM577a Phase 1/2 Pumecitinib Phase 2

Sources

ClinicalTrials.gov NCT06559176

Updated Oct 3, 2026. Something wrong or missing? Report it on the PRME page.

Follow PRME, the company behind PM359

See PRME's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRME catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z